In October 2017 we were able to treat a severely ill asthmatic patient in Calgary ICU with our experimental S1226 drug. Results were in the words of the lead clinician ‘shockingly good’. This case study was presented in May at the American Thoracic Society meeting in San Diego. Full presentation available in poster form.
CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%)
CALGARY, Alberta, November 24, 2015 – SolAeroMed Inc., dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases, today announced its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology by late Fall 2015. “We are very pleased the clinical trial site
SolAeroMed Inc will be attending the European Thoracic Society conference in Amsterdam, Netherlands to present their S-1226 drug and device technologies. Abstract for S-1226 Drug: We have discovered a new short acting bronchodilator represents a new class of bronchodilator. The drug, S-1226, is made up of a gas (4-12% CO2 in air) combined with a synthetic
SolAeroMed management and clinicians attended the American Thoracic Society in Denver, Colorado to present an overview of their current technologies, with a focus on the lead S-1226 drug. The abstract for the presentation can be accessed at: http://www.atsjournals.org/doi. The poster is available here: ATS 2015 Poster
Dr John Dennis, CEO Background SolAeroMed Inc.’s (“SAMi”) drug candidate S-1226 has been under development by the company’s scientific founders since the early 1990s. Their work into the mechanisms underlying a surge in the western Canadian provinces of asthma-related deaths led to the discovery of a novel therapeutic intervention. Patent applications were filed in December
SolAeroMed managment and clinicians are attending, presenting SolAeroMed technology at the following conferences in 2015. Respiratory Drug Delivery, Antibes, Francis: May 5-8 2015 (unconfirmed) American Thoracic Society, Denver: May 15-20, 2015 (confirmed) BIO2015, Philadelphia: June 15-18, 2015 (unconfirmed) European Respiratory Society, Amsterdam: Sept 26-30, 2015 (confirmed) Respiratory Drug Delivery, Phoenix: April 17-21 2016 (confirmed)
Our current clinical trials rely on a unique nebulizer system to delivery a consistent dose and concentration of S1226, and can be readily applied in clinic, Emergency Room and EMS settings. Operational aspects of S1226 neublizer system is demonstrated by John Dennis, SolAeroMed CEO, on this uTube video sponsorted by the nebulizer manufacturer, WestMed, at: http://www.youtube.com/watch?v=J6S6z71dZNk